[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT02650427 : A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection|
|Ages||Min: 18 Years Max: N/A|
- Patients with 18 years old the day of inclusion.
- For women, a negative blood pregnancy test before inclusion is necessary. Note: this
test will be done only to women of childbearing age and non menopausal.
- HCC based on medical imaging with indication of liver resection and without
contra-indication of preoperative liver biopsy.
- Minor resection not exceeding 2 liver segments
- No cirrhosis or cirrhosis with a Child-Pugh Score Class A. Note: this score is used
worldwide to assess liver function in cirrhosis.
- Informed consent must be obtained for all subjects prior to study entry.
- Patients affiliated to health policy insurance.
- Presence of HIV Infection.
- Presence of renal impairment (CrCl <60 ml / min).
- Liver function compromised (Child Pugh B, MELD score > 9)
- Indirect sign of portal hypertension (Oesophagal Varices, splenomegaly, platelet
count less than 100.000)
- A need for major hepatic resection (more than 2 segments)
- Taking digoxin (digitalis) within 6 months of starting treatment.
- History of severe hypersensitivity reaction (such as anaphylactic shock or
angioedema) to sitagliptin.
- Patients with diabetes.
- Pregnant or absence of an effective contraception for women.
- A person deprived of liberty by judicial or administrative decision, person subject
to a legal protection measure.
- Living conditions suggesting an inability to track all scheduled visits by the
- Life expectancy less than 3 months.
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02650427
| Link to official Clinicaltrials.gov listing